Home » Stocks » VALN

Valneva SE (VALN)

Stock Price: $28.15 USD 0.60 (2.18%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 1.38B
Revenue (ttm) 134.54M
Net Income (ttm) -78.53M
Shares Out 48.94M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $28.15
Previous Close $27.55
Change ($) 0.60
Change (%) 2.18%
Day's Open 28.48
Day's Range 28.11 - 28.61
Day's Volume 3,062
52-Week Range 24.16 - 31.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Saint- Herblain ( France) and New York, NY , July 19 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic...

Other stocks mentioned: PFE
1 week ago - GlobeNewsWire

Stocks to buy as the third Covid-19 wave intensifies with the delta variant being dominant globally. Stocks for healthy near-term returns.

Other stocks mentioned: ATVI, DASH, NEM, NFLX, NLS, ZM
1 week ago - InvestorPlace

The FDA grants Breakthrough Therapy Designation to Valneva SE's (NASDAQ: VALN) single-shot chikungunya vaccine candidate, VLA1553. This new U.S. milestone comes in addition to the FDA Fast Track designa...

2 weeks ago - Benzinga

Saint- Herblain (France), July 6 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infect...

2 weeks ago - GlobeNewsWire

Saint Herblain ( France), July 5 , 2021 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infecti...

3 weeks ago - GlobeNewsWire

Saint- Herblain (France), July 1 , 2021 – Following a media article published yesterday, Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and comme...

3 weeks ago - GlobeNewsWire

Saint - Herblain ( France), June 23 , 2021 – Valneva S E (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for in...

1 month ago - GlobeNewsWire

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...

Other stocks mentioned: OCGN, SNY, ARCT, CVAC, NVAX, RDY
1 month ago - InvestorPlace

Here's a list of seven global stocks that can be added to the portfolio for exposure to growth themes from different regions. The post 7 Global Stocks That Are Worth Adding to Your Portfolio appeared fi...

Other stocks mentioned: CPNG, CVAC, EQNR, RADA, SE, XPEV
2 months ago - InvestorPlace

Saint-Herblain (France) – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...

2 months ago - GlobeNewswire

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...

2 months ago - GlobeNewswire

Saint-Herblain (France), May 5, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...

2 months ago - GlobeNewswire

Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...

2 months ago - GlobeNewswire

Valneva SE has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month.

3 months ago - Reuters

About VALN

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2021
CEO
Thomas Lingelbach
Employees
500
Stock Exchange
NASDAQ
Ticker Symbol
VALN
Full Company Profile

Financial Performance

In 2020, Valneva's revenue was 110.32 million, a decrease of -12.58% compared to the previous year's 126.20 million. Losses were -64.39 million, 3,592.3% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Valneva is 35.25, which is an increase of 25.22% from the latest price.

Price Target
$35.25
(25.22% upside)